Tom Brady brings GLP-1s to the masses. Physician burden may be the real cost

Tom Brady recently entered the GLP-1 space as chief wellness officer of eMed, a digital health startup that helps companies manage the high costs associated with covering GLP-1s for their employees. ^[]

Employers—already straining under the cost of covering the increasingly popular weight-loss drugs—are looking for new ways to offer these drugs to workers at scale. And whether clinicians like it or not, those decisions are likely to land squarely in exam rooms.

The pros and cons of GLP-1s as a workplace benefit

Employers have been seeking pressure valves as GLP-1 use has been climbing. Enter employer-facing digital health platforms like eMed, which promise structured access, cost controls, and streamlined monitoring—sometimes with a recognizable face attached. ^[]

For patients, this can mean something new: access to GLP-1s without having to navigate insurance denials or pay four figures out of pocket. For many workers, an employer-sponsored program may be the only realistic way to start therapy. ^[]

Concerns most likely to resonate with healthcare providers wehat’s where concerns raised by Ana Reisdorf, a registered dietitian, recently unpacked the top concerns most likely to resonate with healthcare providers on social media.

She flagged what appears to be a model centered on minimal follow-up—“a quick 60-second check-in through the app”—after an initial prescription encounter that may not involve synchronous care.

Her critique isn’t about celebrity endorsements. It’s about quality.

GLP-1s are not “set it and forget it” medications. They require dose titration, monitoring for GI intolerance and kidney and pancreas problems, and realistic discussions about duration and discontinuation. ^[] These facts are obvious to physicians and other healthcare providers—but not their patients. Compressing that into algorithmic check-ins risks turning obesity treatment into something closer to mail-order dermatology than longitudinal medical care.

How this falls on physicians

The downstream effects of these employer platforms are likely to show up in traditional care settings.

Primary care clinicians may see patients who arrive already on GLP-1s, unsure who is “managing” their medication, or who to call when side effects escalate. Specialists—cardiologists, gastroenterologists, endocrinologists—may inherit complications without clear documentation or continuity of care.

And then there’s nutrition. Rapid weight loss without adequate counseling can mean protein insufficiency, micronutrient deficiencies, or loss of lean mass—issues that don’t always surface until months later, often during routine visits.

The employer–clinician disconnect

What doctors can do

For clinicians, this trend is less about resisting employer-sponsored GLP-1 access and more about preparing for it.

That may mean proactively asking patients where their prescriptions are coming from, documenting who is responsible for ongoing management, and setting clear boundaries around refills and follow-up.

It may also mean advocating—for patients and employers alike—that GLP-1 therapy works best when paired with real clinical oversight, nutrition counseling, and longitudinal care.